Lv71
4960 积分 2023-04-18 加入
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
3天前
已完结
A First-in-Class JAK/ROCK Inhibitor, Rovadicitinib, for Glucocorticoid-Refractory or -Dependent Chronic GVHD
5天前
已完结
Advances in Stem Cell Transplantation for Myelofibrosis
29天前
已完结
Haploidentical Hematopoietic Cell Transplantation for Myelofibrosis in the Ruxolitinib Era
1个月前
已完结
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
1个月前
已完结
Phase II Prospective Study of Intentional Pre-Treatment of Hematopoietic Cell Transplant Eligible Myelofibrosis Patients with Ruxolitinib
1个月前
已关闭
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
1个月前
已完结
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
1个月前
已完结
Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies
1个月前
已关闭
Phase II Single Center Prospective Study of Ruxolitinib in Addition to Standard Graft Versus Host Disease Prophylaxis in Patients with Myelofibrosis Demonstrates Encouraging Outcomes
1个月前
已完结
皖公网安备34019202002308
